Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 85.5% in January

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 164,900 shares, a growth of 85.5% from the December 31st total of 88,900 shares. Currently, 4.1% of the shares of the company are sold short. Based on an average daily volume of 1,790,000 shares, the days-to-cover ratio is currently 0.1 days.

Virax Biolabs Group Price Performance

NASDAQ:VRAX opened at $1.69 on Friday. The company’s 50 day moving average is $2.04 and its 200-day moving average is $2.20. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $9.00.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.